Please check your internet connection and try again.
# Walethmade Bromide
## Overview
Walethmade bromide is a quaternary ammonium compound used as a respiratory tract anticholinergic agent.
## Primary Indications
* Adjunctive treatment for reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
## Adult Dosing
* **Inhalation:** 125-250 mcg (mcg) delivered via metered-dose inhaler (MDI) or nebulizer.
* **Frequency:** Typically every 6-8 hours.
* **Maximum Dose:** Not explicitly defined, but adherence to recommended frequency is advised. Dosing may vary based on individual response and local protocols.
## Pediatric Dosing
* Dosing for pediatric patients is not well-established. Use with caution and at the discretion of the prescribing physician.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustments are routinely recommended, but caution may be warranted in severe renal impairment.
* **Hepatic Impairment:** No specific dose adjustments are routinely recommended.
## Contraindications
* Hypersensitivity to ipratropium bromide or atropine.
* History of hypersensitivity to soybeans or peanuts (due to lecithin in some MDI formulations).
## Adverse Effects
* **Common:** Headache, cough, dry mouth, throat irritation, upper respiratory tract infection, dizziness, nausea, blurred vision, gastrointestinal upset.
* **Less Common/Serious:** Bronchospasm (paradoxical), urinary retention, glaucoma, severe allergic reactions (anaphylaxis).
## Key Drug Interactions
* **Other Anticholinergics:** Increased risk of anticholinergic side effects.
* **Beta-2 Agonists:** May enhance bronchodilation.
## Monitoring
* Respiratory status (wheezing, shortness of breath).
* Signs of urinary retention.
* Signs of acute angle-closure glaucoma (eye pain, blurred vision, visual halos).
## Clinical Pearls
* Administer cautiously in patients with a history of narrow-angle glaucoma or prostatic hyperplasia.
* For MDI use, instruct patients on proper inhaler technique.
* If used concurrently with a beta-agonist inhaler, the beta-agonist should typically be administered first to improve bronchodilation.
* Onset of action is slower than short-acting beta-agonists.
***
*This information is intended for healthcare professionals. Always consult the official prescribing information and your institution's protocols for the most current and complete drug information.*
